PharmaCyte Biotech Inc (PMCB)

[concordia]

I would not be surprised at all if the FDA made them start at P1. The clinical data is very old and probably not done under the same protocols that are required today. The fact that the trial material is different then those used in the late 90's trial (although the current material may be superior) could be a big problem. This stock cannot take a bad news hit at this level. Those who pretend to "not care" about the stock price are not being honest as the lower this goes the point will come where raising money will be impossible.